Form 4: AMN Healthcare CLO Reports Scheduled Equity Transactions

AMN Healthcare's Chief Legal Officer, Whitney M. Laughlin, reported scheduled equity transactions including RSU vesting, tax-related dispositions, and new RSU grants, effective January 15, 2026, under a Rule 10b5-1(c) plan.

Summary

• Whitney M. Laughlin, Chief Legal Officer of AMN Healthcare Services Inc. (AMN), reported equity transactions occurring on January 15, 2026.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• A total of 4,488 shares of common stock were acquired through the vesting of Restricted Stock Units (RSUs) from grants made in 2023, 2024, and 2025.
• A total of 1,332 shares of common stock were disposed of to cover tax withholding obligations at a price of $19.55 per share.
• A new grant of 19,641 Restricted Stock Units was made on January 15, 2026, which will vest in three tranches on each of the first, second, and third anniversaries of the grant date.
• Following these transactions, Laughlin beneficially owns 23,652 shares of common stock directly and 47,236 derivative securities (Restricted Stock Units) directly.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled executive equity transactions (RSU vesting, tax withholding, new grants) which are neutral in terms of immediate positive or negative sentiment for the company's operational performance or stock price.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the achievement of service-based conditions and conversion of equity incentives into common stock, reflecting continued executive tenure.
• A new grant of 19,641 Restricted Stock Units demonstrates ongoing executive incentive alignment with shareholder interests and continued commitment to the company.
• Transactions were pre-planned under a Rule 10b5-1(c) plan, indicating a structured and compliant approach to executive equity management.

Negatives

• The disposition of 1,332 shares for tax withholding purposes reduces the direct common stock holdings, though this is a standard and expected practice for RSU vesting.

Future Outlook

The filing primarily details past and scheduled equity transactions for an executive and does not provide forward-looking statements or guidance on the company's operational or financial performance.

Industry Context

This Form 4 filing is a routine disclosure of executive equity compensation and does not provide specific insights into broader industry trends or competitive landscape. Such transactions are common across publicly traded companies as part of executive incentive programs.

Stakeholder Impact

• Shareholders: The report indicates routine executive compensation practices, which are generally expected and align executive interests with long-term company performance through equity ownership.
• Employees: The RSU grants serve as an incentive for executive retention and performance.

Next Steps

• Future tranches of the 2024, 2025, and 2026 RSU grants will vest on their respective anniversaries, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled executive equity transactions, including RSU vesting and new grants, executed under a Rule 10b5-1(c) plan. Such disclosures are standard and do not typically provide new material information that would warrant a change in investment recommendation. The transactions reflect ongoing executive compensation and alignment with shareholder interests rather than a change in the company's fundamental outlook.

Keywords

AMN Healthcare, AMN, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Equity Plan, Form 4, Rule 10b5-1